CTIS.eu › Cities › Spain › Sevilla
Sevilla
Spain
1,630 total trials
639 recruiting
Filter these 1,630 trials by phase, condition, sponsor and more.
Open in Search →
2023-507324-23-00
4
2024-05-22
recurrent or persistent uterine serous carcinoma
2023-508440-21-00
5
2024-05-21
Infections due to Enterobacteriaceae
2023-506881-30-00
3
2024-05-15
Melanoma
2023-506238-61-00
5
2024-05-10
Phenylketonuria
2023-503223-26-00
9
2024-05-07
Advanced Solid Tumors Harboring a KRASG12C Mutation
2023-504583-42-00
4
2024-05-07
Overweight or Obesity and Chronic Kidney Disease With or Without Type
2023-505919-21-00
4
2024-04-25
Heart failure with preserved ejection fraction (HFpEF)
2023-507217-10-00
5
2024-04-12
Thyroid eye disease
2023-506432-32-00
6
2024-04-11
Latent tuberculosis infection in patients with end-stage kidney diseas
2022-501421-20-00
5
2024-04-09
Gout with hyperuricemia
2022-501969-42-00
5
2024-03-28
Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criter
2023-508161-32-00
4
2024-03-28
Thyroid Eye Disease
2023-506236-32-00
5
2024-03-25
Pneumococcal disease
2023-507125-41-00
9
2024-03-25
Advanced or Metastatic Breast Cancer
2024-512635-71-00
4
2024-03-14
Solid tumors
2023-504678-39-00
4
2024-03-13
Heart Failure
2023-505520-61-00
10
2024-03-11
Systemic Lupus Erythematosus
2023-505499-32-00
5
2024-03-08
Uncontrolled hypertension (uTHN) defined as blood pressure that remain
2023-503910-60-00
4
2024-03-05
Rheumatoid arthritis
2023-505396-71-00
4
2024-03-01
Early Alzheimer’s Disease with Biomarkers of Inflammation
2023-507358-34-00
4
2024-02-13
For the treatment of patients with chronic non-specific low back pain
2023-507304-32-00
6
2024-02-09
Chronic Obstructive Pulmonary Disease
2023-504809-37-00
5
2024-02-07
Symptomatic Obstructive Hypertrophic Cardiomyopathy
2023-506197-12-00
4
2024-02-07
Dyslipidemia
Dyslipidemias are alterations to the plasma lipid profile
Showing 1,297–1,320 of 1,630 trials